Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
her-2 chimeric immune receptor t cells
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
HER-2 chimeric immune receptor T cells (also known as HER2 CAR-T cells) are an adoptive cellular immunotherapy consisting of T lymphocytes genetically engineered to express a chimeric antigen receptor (CAR) targeting the Human Epidermal Growth Factor Receptor 2 (HER2/neu). These cells are designed to recognize and eliminate HER2-expressing tumor cells in a non-MHC-restricted manner. Early research, such as that conducted at the University of Pennsylvania, demonstrated that HER2 is widely expressed in ovarian cancer and that these engineered T cells can effectively target and kill primary tumor cells derived from patients, providing a rationale for clinical development in advanced ovarian carcinoma.
- Other names
- HER2 CAR-T cellsHER-2 CAR-T cellsHER 2 CAR-T cellsHER2-specific CAR-T cellsHER-2-specific CAR-T cellsHER 2-specific CAR-T cellsHER-2 CIR T cellsHER2 CIR T cellsHER 2 CIR T cellsHER2-directed CAR-T cellsHER-2-directed CAR-T cellsHER 2-directed CAR-T cells
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on her-2 chimeric immune receptor t cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on her-2 chimeric immune receptor t cells.